4 - 7 February 2025 Milan
![]() |
![]() |
![]() |
![]() |
3-NUR | Interim results from the Lived Experience of von Willebrand Disease (vWD 360) study | Kate Khair | ![]() |
![]() |
|||
3-PO | APTT Mixing Studies-Pilot survey: Results and analysis from the UK NEQAS BC Haemophilia programmes 2024 | Anna Williams | ![]() |
![]() |
|||
4-PT | Measurement properties of a core outcome set monitoring physical capability in people with haemophilia | David Stephensen | ![]() |
![]() |
|||
5-PO | Ex vivo Comparison of Mim8 Combined with Activated Factor XI Versus Tissue Factor in Thrombin Generation Assays | Kati Rehberg | ![]() |
![]() |
|||
15-PO | Diagnosis of assay discrepancy in mild haemophilia A using chromogenic FVIII:C with extended incubation time | Annette Bowyer | ![]() |
![]() |
|||
16-PO | High-quality standardised ELISA to manage dose adjustments during concizumab prophylaxis in patients with haemophilia A/B with and without inhibitors in the routine clinical setting: Test access model description | Naveen Shridhar | ![]() |
![]() |
|||
17-PO | Lipoprotein (a) in hemophilia A and B patients | Tuukka Helin | ![]() |
![]() |
|||
18-PO | Progress and Challenges in Hemophilia Management at BDTH-KASU Hemophilia Treatment Center, Kaduna | Lgdogara Dr. Livingstone Gayus Dogara | ![]() |
![]() |
|||
23-PO | Pharmacokinetic evaluation of extended half-life versus standard half-life factor VIII: Real-life conditions | Natalia duque Zapata | ![]() |
![]() |
|||
24-PO | D-dimers levels in patients with haemophilia A and B | Brigitte Tardy | ![]() |
![]() |
|||
25-PO | Natural history of AAV5 neutralising antibodies in adults with haemophilia B during =6-month screening and lead-in to the HOPE-B trial with etranacogene dezaparvovec gene therapy | Janeen Nuttall | ![]() |
![]() |
|||
28-PO | Role of Factor VIII in Promoting Endothelial Cell Function and Membrane Stability | Gillian Patman | ![]() |
![]() |
|||
29-PO | Role of factor VIII in the regulation of endothelial cell function and extracellular matrix protein expression | Gillian Patman | ![]() |
![]() |
|||
30-PO | Impact of variable recombinant factor VIII binding on platelet functions | Gillian Patman | ![]() |
![]() |
|||
31-PO | Characterization of a F8-/-IgH-/- double knockout mouse model of hemophilia A for long-term exposure to factor VIII products | Gillian Patman | ![]() |
![]() |
|||
35-PO | Efficacy and safety of concizumab prophylaxis in patients with haemophilia and inhibitors: Results from the Early Access Program in France | Alexandre Butelet | ![]() |
![]() |
|||
38-PO | PedNet real world experience of emicizumab prophylaxis started in PUPs and MTPs with severe hemophilia A | Marloes de Kovel | ![]() |
![]() |
|||
41-PO | Growing up with N9-GP: Safety and efficacy of prophylaxis for up to eleven years in children with haemophilia B | Sarah Christopher | ![]() |
![]() |
|||
42-PO | Evaluation of the risk factor for developing cardiovascular diseases in adult Japanese hemophiliacs | Yushi Chikasawa | ![]() |
![]() |
|||
47-PO | Patient characteristics in FREEDOM, a study evaluating physical activity and joint health in patients with haemophilia A receiving efanesoctocog alfa prophylaxis | Costello Medical | ![]() |
![]() |
|||
50-PO | Investigating the risk of intravenous ferric carboxymaltose (FCM)-induced hypophosphatemia in patients with inherited bleeding disorders at Sheffield Teaching Hospitals (STH). | Gary Deakin | ![]() |
![]() |
|||
54-PO | A real world study of haemophilia treatment satisfaction, bleeds, health related quality of life as reported by patients and physicians to demonstrate gaps. | Valeria Merla | ![]() |
![]() |
|||
60-PO | Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults and Adolescents with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Long-term Extension Study | Jo McCarthy | ![]() |
![]() |
|||
63-PO | Valoctocogene roxaparvovec estimated long-term durability of treatment effect: An extrapolation of the most recent clinical data | Gillian Clague | ![]() |
![]() |
|||
64-PO | Number needed to scan with Point-of-care Ultrasonography for screening hemarthrosis in hemophilia patients | Natalia Duque | ![]() |
![]() |
|||
67-PO | Unmet Needs of Patients With Haemophilia A/B With or Without Inhibitors: Real-World End-of-Study Results From the explorer6 Non-Interventional Study | Giancarlo Castaman | ![]() |
![]() |
|||
69-PO | How to increase joint disease assessment in patient with haemophilia: from theory to practice | ignazio Iasiello | ![]() |
![]() |
|||
71-PO | Developing Evidence-Based Guidelines for AAV Gene Therapy in Hemophilia | Donna Coffin | ![]() |
![]() |
|||
75-PO | Subclinical Joint bleeding in Patients with Hemophilia: A Systematic Review | Fahad Alabbas | ![]() |
![]() |
|||
79-PO | Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study | Costello Medical | ![]() |
![]() |
|||
80-PO | Association of Bleeding Rate and ABO Blood Group with Prophylaxis in Non-Severe Hemophilia A | David Schmidt | ![]() |
![]() |
|||
82-PO | Final analysis of the phase 1/2 trial of valoctocogene roxaparvovec for severe hemophilia A | Priyanka Raheja | ![]() |
![]() |
|||
83-PO | Annualised Bleeding Rates in Patients with Haemophilia A or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 explorer7 Study | Silvia Linari | ![]() |
![]() |
|||
88-PO | Real-world bleeding rates of people with severe haemophilia A on emicizumab treatment in the Netherlands with and without a history of an inhibitor | Elisabeth Taal | ![]() |
![]() |
|||
93-PO | Long-term data of the effect of ankle joint distraction in hemophilic arthropathy | Lize van Vulpen | ![]() |
![]() |
|||
95-PO | Joint health in women with hemophilia- reality in 2024- a survey | Rosa Sonja Alesci | ![]() |
![]() |
|||
96-PO | TSUBASA: A prospective study evaluating association between physical activity and bleeding events, quality of life, and safety in people with haemophilia A without factor VIII inhibitors | Helen Miller | ![]() |
![]() |
|||
102-PO | Shared Decision Making Around Emicizumab Dosing Frequency to Support Adherence | Natasha Longsmith | ![]() |
![]() |
|||
104-PO | Real-World Effectiveness of Eptacog Beta Coagulation Factor VIIa (Recombinant) in the USA | PASCALINE BELLEVILLE-BOISSAYE | ![]() |
![]() |
|||
107-PO | UK survey of patient perspectives of dental care when living with a bleeding disorder. | Debra Morgan | ![]() |
![]() |
|||
109-PO | Clinical outcomes over 3 years of efanesoctocog alfa in adults and adolescents with severe haemophilia A: European results from the second interim analysis of XTEND-ed | Liz Southey | ![]() |
![]() |
|||
110-PO | Retrospective Analysis of Pregnancy and Birth Outcomes in Hemophilia Carriers: A 10-Year Review of Known and Undiagnosed Cases from Southern Italy | Marta Mattana | ![]() |
![]() |
|||
118-PO | Acquired Hemophilia-management strategies: A single center experience | Liat Waldman Radinsky | ![]() |
![]() |
|||
119-PO | Advocacy to improve the quality of educational initiatives for patients with rare bleeding disorders: proposed methodology | Thomas Sannié | ![]() |
![]() |
|||
120-PO | Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study | Costello Medical | ![]() |
![]() |
|||
133-PO | Feasibility of tests for motor skills (general fitness, proprioception and balance) in patients with hemophilia and association with pain and orthopedic joint status | Katharina Holstein | ![]() |
![]() |
|||
135-PO | Management of pregnancy in women with inherited bleeding disorders; 10 years of experience in managing haemophilia carriers and von Willebrands disease within 2 Haemophilia comprehensive care centres within the UK | Emily Millen | ![]() |
![]() |
|||
139-PO | Innovative tool as part of educational workshops for reporting on learning by teenagers living with hemophilia | Thomas Sannié | ![]() |
![]() |
|||
140-PO | Are Women Welcome in Haemophilia Clinical Trials? | Meaghan ODonnell | ![]() |
![]() |
|||
142-PO | Enhancing Global Collaboration: The Role of Data Governance in the WFH Gene Therapy Registry | Mayss Naccache | ![]() |
![]() |
|||
144-PO | Single center experience of efanesoctocog alfa in adult and pediatric patients withhemophilia A. | Kim Schafer | ![]() |
![]() |
|||
148-PO | Clinical outcomes over 2 years of efanesoctocog alfa in children with severe haemophilia A: European results from the second interim analysis of XTEND-ed | Liz Southey | ![]() |
![]() |
|||
151-PO | Deciding type of prophylaxis in previously untreated / minimally treated infants with hemophilia: Report from a pediatric center | Marina Economou | ![]() |
![]() |
|||
152-PO | Developing a Prioritized Set of Advocacy Indicators for Enhanced Hemophilia Care in Africa Using WBDR and AGS Data | Donna Coffin | ![]() |
![]() |
|||
163-PO | Patient Views on Transitioning from Emicizumab to Efanesoctocog Alfa Prophylaxis: Results from an Online Survey | Evelien Krumb | ![]() |
![]() |
|||
175-PO | Real world experience with the use of Emicizumab in hemophilia A patients with and without inhibitors in Morocco :Insights from a low- and middle-income country. | Nisrine Khoubila | ![]() |
![]() |
|||
192-PO | Management of patients with hemophilia undergoing percutaneous coronary intervention: pre and post-operative treatment | Gianluca Sottilotta | ![]() |
![]() |
|||
202-PO | The hemorrhagic profile of hemophiliacs with inhibitors Experience of CHU Oran | Cherif hosni Aicha | ![]() |
![]() |
|||
208-PO | Real-world quality of life data in patients with haemophilia A and haemophilic arthropathy after 1 year of emicizumab therapy | Karla Rener | ![]() |
![]() |
|||
215-PO | Case report of Emicizumab in young patient with acquired haemophilia | Emily Millen | ![]() |
![]() |
|||
216-PO | EXPERIENCE WITH EMICIZUMAB IN PATIENTS WITH MODERATE-SEVERE HEMOPHILIA A IN OUR CENTER | Cristina Vaz Silva | ![]() |
![]() |
|||
224-PO | Reviewing the diagnosis of von Willebrand disease using new laboratory tests and recent consensus guidelines in paediatric patients attending the Paediatric Coagulation Centre at Childrens Health Ireland at Crumlin | Beatrice Nolan | ![]() |
![]() |
|||
237-PO | Self-BAT and PBAC Scores in Adolescents From The General Dutch Population: Results From The Menstruation Education Calendar App. | Anne de Vaan | ![]() |
![]() |
|||
242-PO | Increased prophylactic dosing frequency reduces bleeding in von Willebrand disease patients requiring more haemostatic coverage | Gillian Patman | ![]() |
![]() |
|||
243-PO | Title: Health-related quality of life of French adults with von Willebrand disease: WiSH-QoL study results according to von Willebrand factor (VWF: RCo) activity levels. | Marie-Hélène ANDRE-BONNET | ![]() |
![]() |
|||
245-PO | The Significance of von Willebrand Factor Multimer analysis in the Clinical Classification of von Willebrand Disease: A Centres Experience | PANAGIOTIS CHRISTOFOROU | ![]() |
![]() |
|||
247-PO | Regular prophylaxis with a 1:1 von Willebrand factor/Factor VIII concentrate is effective for reducing joint and muscle bleeds in children and adults with von Willebrand disease | Gillian Patman | ![]() |
![]() |
|||
249-PO | Safety of von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at delivery | Yaquine Mechelfekh | ![]() |
![]() |
|||
250-PO | von Willebrand factor (VWF:RCo) activity levels have an impact on health-related quality of life of adolescents with von Willebrand disease (VWD) and their family | Marie-Hélène ANDRE-BONNET | ![]() |
![]() |
|||
251-PO | Efficacy and Safety of Prophylaxis with a Plasma-derived von Willebrand Factor/Factor VIII Concentrate in Male and Female Patients with von Willebrand Disease | Gillian Patman | ![]() |
![]() |
|||
256-PO | Efficacy of Prophylactic Emicizumab in Type III Von Willibrand Disease Patients: A Report of Two Cases. | ohoud kashari | ![]() |
![]() |
|||
260-PO | Use of thalidomide for refractory bleeding in von Willebrand disease. | Olga Tsiamita | ![]() |
![]() |
|||
275-PO | Management of pregnancy and childbirth in Glanzmann Thrombasthenia: a scoping review | Karlijn Rutten | ![]() |
![]() |
|||
277-PO | FXI deficiency beyond bleeding- is there a higher risk for allergic diseases? | Rosa Sonja Alesci | ![]() |
![]() |
|||
283-PO | Update on a Phase 3 Study of a Double Virus-Inactivated Human Antithrombin Concentrate During Surgery or Childbirth in Patients with Congenital Antithrombin Deficiency | Sarah Baker | ![]() |
![]() |
|||
292-PO | Management of Glanzmann Disease: Understanding Management of Anti-Platelet Antibodies via a European Survey | Mathieu Fiore | ![]() |
![]() |
|||
295-PO | SURGICAL PROPHYLAXIS IN PATIENTS WITH RARE COAGULATION FACTOR DEFICIENCIES: EXPERIENCE FROM A SECOND-LEVEL HOSPITAL | Carmen Gil Barroso | ![]() |
![]() |
|||
299-PO | Successful subcutaneous infusion of plasmatic F VII - concentrate for bleeding prophylaxis | Wolfgang Eberl | ![]() |
![]() |
|||
305-PO | Efficacy and Safety of a New Human Fibrinogen Concentrate for Treatment of Bleeding Events in Patients with Congenital Fibrinogen Deficiency | Eugenio Rosado | ![]() |
![]() |
|||
318-PO | An Audit of the Diagnosis of Bleeding Disorder of Unknown Cause | Chi-Jun Chan | ![]() |
![]() |
|||
331-PO | Light transmission aggregometry is not suitable for monitoring hemostatic changes after platelet transfusion in Glanzmann thrombasthenia | Karlijn Rutten | ![]() |
![]() |
|||
336-PO | Severe FV deficiency leading To Intracranial haemorrhage | Renester Fenton | ![]() |
![]() |
|||
338-PO | Management of acquired factor X deficiency in a patient with multiple myeloma: a case study | Filomena Daniele | ![]() |
![]() |
|||
352-PO | Nurse Therapeutic Education Management for patients with non-acquired haemophilia treated with Emicizumab in France | Celine CHENUEL | ![]() |
![]() |
|||
359-PO | Educational Needs of Health Care Providers regarding Women and Girls with Bleeding Disorders an online survey | Gaelle Notzli | ![]() |
![]() |
|||
362-PO | Unmet Clinical and Psychosocial Needs in Women with Coagulopathies: Findings from a National Meeting | LAURA QUINTAS | ![]() |
![]() |
|||
367-PO | Occupational Therapy - The Developing role of Occupational Therapy within Haemophilia ServicesHaemophilia Comprehensive Care Centre, Belfast Health & Social Care Trust | Claire Forde | ![]() |
![]() |
|||
370-PO | Exploring unmet patient needs in haemophilia: a qualitative study on joint bleed treatment in the US | Enrico Mastroianni | ![]() |
![]() |
|||
373-PO | Factors Associated with Health-Related Quality of Life in Obligate Carrier Women of Haemophilia | Claudia Sossa | ![]() |
![]() |
|||
378-PO | Remote Monitoring of Physical Function in Children with Haemophilia: Reliability of Telehealth for the Six-Minute Walk, Vertical Jump, and Triple Hop Tests | David Stephensen | ![]() |
![]() |
|||
385-PO | An examination of barriers and facilitators to physical activity and sports participation in children and adolescents with haemophilia (in Ireland). | Paula Loughnane | ![]() |
![]() |
4 - 7 February 2025 Milan
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|